Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Doses First Patient in China Trial of CD73 Antibody

publication date: May 13, 2020

Shanghai's I-Mab Biopharma has dosed the first patient in a China Phase I/II trial of its CD73 antibody, TJD5, in patients with advanced solid tumors. TJD5 will be tested as a monotherapy and in combination with Junshi Pharma's PD-1, Tuoyi®. The trial will enroll patients with advanced or metastatic cancer. In the US, I-Mab has started tests of the CD73 candidate with a Roche PD-L1 antibody. I-Mab expects TJD5 may address the low response rates of PD-1/PD-L1 therapies in solid tumors. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here